Purpose: This single-arm, multicenter, phase-II trial evaluated the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) using fine-powder cisplatin and iodized-oil suspension in patients with intermediate- and advanced-stage [Barcelona Clinic Liver Cancer (BCLC) stage-B and stage-C] hepatocellular carcinomas (HCCs).
Methods: The Institutional Review Board approved this study and patients provided written informed consent. Thirty-five patients (24 men and 11 women, mean 74 ± 6 years [range 60-87 years]) with BCLC stage-B (57 %, 20/35) or stage-C (43 %, 15/35) HCCs who were not candidates for other locoregional treatments were enrolled. HAIC was performed using a suspension of fine-powder cisplatin with a maximum dose of 65 mg/m(2) and iodized oil on demand. The primary endpoint was the response rate evaluated based on Response Evaluation Criteria in Solid Tumor (RECIST) and modified RECIST (mRECIST). Secondary endpoints were overall survival, progression-free survival, and safety.
Results: The initial and best overall response rates at 4 weeks and 3 months, respectively, were 14 and 17 % based on RECIST, and 57 and 23 % based on mRECIST. The median overall and progression-free survival times were 18 and 4 months, respectively. The most frequent grade-3 or grade-4 adverse events were elevation of serum alanine (23 %) and aspartate aminotransferase (20 %), and thrombocytopenia (17 %).
Conclusion: This HAIC provides promising therapeutic effects with acceptable safety to patients with intermediate-stage and advanced-stage HCCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10147-014-0773-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Moringa oleifera leaves extract loaded gold nanoparticles offers a promising approach in protecting against experimental nephrotoxicity.
Prostaglandins Other Lipid Mediat
February 2024
Medical Biochemistry Department, National Research Centre, Dokki 12622, Egypt.
Cisplatin is one of the most important antitumor drugs, however; it has numerous adverse effects like nephrotoxicity which is considered one of cisplatin uses . The study was planned to evaluate the nephroprotective effect of M. oleifera leaves extract loaded gold nanoparticles (Au-NPs) against cisplatin-induced nephrotoxicity in rats.
View Article and Find Full Text PDFClinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion.
Cancers (Basel)
September 2021
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Macroscopic vascular invasion (MVI) is a poor prognostic factor in hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) is a promising treatment in MVI-HCC. However, it is not clear which regimens are suitable for HAIC.
View Article and Find Full Text PDFSurvival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Cancers (Basel)
February 2021
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Backround: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC.
Methods: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy.
Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma.
Jpn J Radiol
May 2021
Department of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, 666-2, Nitonatyo, Chuouku, Chiba, 260-0801, Japan.
Article Synopsis
- The study aimed to assess the safety and effectiveness of a treatment called whole-liver transcatheter arterial chemoinfusion and bland embolization (TACBE) using cisplatin and microspheres for patients with unresectable multinodular hepatocellular carcinoma (HCC).
- A total of 15 patients were reviewed, showing a 1-year overall survival (OS) rate of 64.6%, with manageable side effects primarily involving increased liver enzymes.
- The treatment demonstrated a 54.5% objective response rate and 68.2% disease control rate, indicating that TACBE was both well-tolerated and effective for these patients.
Recent advances in medical management of hepatocellular carcinoma.
Hepatol Res
January 2019
Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
Article Synopsis
- Transcatheter arterial therapies for hepatocellular carcinoma (HCC) have seen advancements, including the adoption of platinum agents like cisplatin and miriplatin in Japan for chemoembolization treatments.
- While techniques like balloon-occluded TACE and drug-eluting microspheres show promise, their specific benefits over traditional methods are still unclear, especially for patients with intermediate stage HCC which is a complex category with varying prognoses.
- In advanced HCC, recent phase III trials have identified effective systemic chemotherapies such as lenvatinib and several second-line options, with future prospects for molecular-targeted and immune-therapy advancements, particularly for TACE-resistant cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!